Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

Bone Marrow Transplantation volume 42, pages 23–28 (2008)Cite this article

Abstract

A total of 72 patients with Ph-positive CML in first chronic phase were followed during a 6-year period in two different institutions in México. Among them, 22 were given a reduced-intensity allogeneic SCT, whereas 50 were given a tyrosine kinase inhibitor (TKI), mainly imatinib mesylate. The 6-year overall survival (OS) after the therapeutic intervention for patients allografted or given a TKI was 77 and 84%, respectively (P, NS); the median OS for both groups has not been reached, being above 90 and 71 months, respectively (P, NS). The freedom from progression to blast or accelerated phases was also similar for both groups, as well as the overall OS after diagnosis. Most patients allografted (91%) chose this treatment because they were unable to afford continuing treatment with the TKI, whereas most treated with the TKI (84%) were given the treatment without charge, through institutions able to pay for their treatment. The median cost of each nonmyeloablative allograft was US$18 000, an amount that is enough to cover 180 days of treatment with imatinib (400 mg per day) in México. Cost considerations favor allogeneic SCT as a ‘once only’ procedure whereas lifelong treatment with an expensive drug represents an excessive burden on resources.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Goldman JM . Advances in CML. Clin Adv Hematol Oncol 2007; 5: 270–272.

    PubMed  Google Scholar 

  2. Gómez-Almaguer D . Leucemias crónicas. In: Ruiz-Argüelles GJ (ed). Fundamentos de Hematología, 3rd edn. Editorial Médica Panamericana: México City, 2004, pp 246–260.

    Google Scholar 

  3. Ruiz-Argüelles GJ, López-Martínez B, Ramírez-Cabrera JM, Reyes-Nuñez V, Rodríguez-Cedeño H, Garcés-Eisele J . Molecular monitoring of the treatment of patients with BCR/ABL(+) chronic myelogenous leukemia. Rev Invest Clín Méx 2001; 53: 235–239.

    Google Scholar 

  4. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.

    Article  CAS  PubMed  Google Scholar 

  5. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O . Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894–896.

    PubMed  Google Scholar 

  6. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, et al., Latin American Cooperative Oncohematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047.

    Article  PubMed  Google Scholar 

  7. Okamoto S, Watanabe R, Takahashi S, Mori T, Izeki T, Nagayama H et al. Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. Int J Hematol 2002; 75: 493–498.

    Article  CAS  PubMed  Google Scholar 

  8. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.

    Article  CAS  PubMed  Google Scholar 

  9. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  10. Gratwohl A, Baldomero H, Labar B, Apperley J, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J 2004; 45: 689–694.

    PubMed  Google Scholar 

  11. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    Article  CAS  PubMed  Google Scholar 

  12. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD . Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1998; 71: 723–727.

    Google Scholar 

  13. Ruiz-Argüelles A . Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735–743.

    Google Scholar 

  14. Ruiz-Argüelles A, Orfao A . Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF (eds). Actualización en Leucemias. Editorial Médica Panamericana: México City, 1996, pp 79–82.

    Google Scholar 

  15. Pinkel D, Straume T, Gray JW . Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1996; 83: 2934–2938.

    Article  Google Scholar 

  16. Yam P, Petz L, Knowlton R, Wallace R, Stock A, deLange G et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987; 43: 399–407.

    Article  CAS  PubMed  Google Scholar 

  17. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros F et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution. Rev Invest Clin Mex 2000; 52: 118–124.

    Google Scholar 

  18. Kaplan EL, Meier P . Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457–463.

    Article  Google Scholar 

  19. Hehlmann R, Hochhaus A, Baccarani M . European Leukemia Net: chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

    Article  CAS  PubMed  Google Scholar 

  20. Druker BJ, Guilhot F, O'Brien SO, Larson RA, on behalf of the IRIS. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: the 5-year update from the IRIS study. J Clin Oncol 2006; 24 (suppl): 6506.

    Google Scholar 

  21. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE . Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant 2000; 25: 131–133.

    Article  PubMed  Google Scholar 

  22. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC . Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241–244.

    Article  PubMed  Google Scholar 

  23. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083–1088.

    Article  CAS  PubMed  Google Scholar 

  24. Basara N, Roemer E, Kraut L, Guenzelmann S, Schmetzer B, Kiehl MG et al. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant 2002; 30: 651–659.

    Article  CAS  PubMed  Google Scholar 

  25. Khoury H, Adkins D, Brown R, Pence H, Vij R, Goodnough LT et al. Low incidence of transplantation related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 2001; 7: 352–358.

    Article  CAS  PubMed  Google Scholar 

  26. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S . Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125–129.

    Article  CAS  PubMed  Google Scholar 

  27. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005; 11: 272–279.

    Article  PubMed  Google Scholar 

  28. Gómez-Almaguer D . The simplification of the stem cell procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76 (Suppl 1): 380–382.

    Article  PubMed  Google Scholar 

  29. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Delgado GJ, Tarín-Arzaga LC . Ocho años de experiencia con el ‘método Mexicano’ en la realización de trasplantes de células hematopoyéticas alogénicas. Gac Med Mex 2007; 143: 231–235.

    PubMed  Google Scholar 

  30. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft versus-host-disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–185.

    Article  PubMed  Google Scholar 

  31. Battiwalla M, Barrett J . Allogeneic transplantation using non-myeloablative transplant regimens. Best Pract Res Clin Haematol 2001; 14: 701–722.

    Article  CAS  PubMed  Google Scholar 

  32. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua A, Frauendorfer K . Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe. Impact of cost considerations. Leukemia 2007; 21: 383–386.

    Article  CAS  PubMed  Google Scholar 

  33. Gajewski JL, Robinson P . Do affluent societies have the only option for the best therapy? Leukemia 2007; 21: 387–388.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro de Hematología y Medicina Interna, Clinica Ruiz, Puebla, México

    G J Ruiz-Argüelles, K I Gutierrez-Riveroll & R Rangel-Malo

  2. Laboratorios Clínicos de Puebla, Clinica Ruiz, Puebla, México

    G J Ruiz-Argüelles, M L Gonzalez-Carrillo & R Rangel-Malo

  3. Departamento de Hematología, Hospital Universitario, Monterrey, México

    L C Tarin-Arzaga, C H Gutiérrez-Aguirre, O G Cantú-Rodríguez & D Gómez-Almaguer

  4. Department of Hematology, MD Anderson Cancer Center, Houston, TX, USA

    S Giralt

Authors
  1. G J Ruiz-Argüelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L C Tarin-Arzaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M L Gonzalez-Carrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K I Gutierrez-Riveroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Rangel-Malo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C H Gutiérrez-Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O G Cantú-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Gómez-Almaguer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G J Ruiz-Argüelles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruiz-Argüelles, G., Tarin-Arzaga, L., Gonzalez-Carrillo, M. et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?. Bone Marrow Transplant 42, 23–28 (2008). https://doi.org/10.1038/bmt.2008.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.90

Keywords

This article is cited by

Search

Advanced search

Quick links